Research programme: neurological disorders therapeutics - Panacea Pharmaceuticals
Latest Information Update: 09 Jul 2007
At a glance
- Originator Brown University; Rhode Island Hospital
- Mechanism of Action Antioxidants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 03 Jul 2002 Preclinical trials in Neurological disorders in USA (unspecified route)